ISLET TRANSPLANTATION IN TYPE I DIABETIC REICIPIENTS OF RENAL ALLOGRAFT USING TH

使用 TH 进行同种异体肾移植的 I 型糖尿病患者的胰岛移植

• 批准号: 7606916
• 负责人: MARTHA PAVLAKIS
• 金额: $ 0.41万
• 依托单位: BETH ISRAEL DEACONESS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7606916
• 关键词: Canada; Computer Retrieval of Information on Scientific Projects Database; Evaluation; Feasibility Studies; Funding; Grant; Harvest; Immune response; Immunosuppression; Individual; Infusion procedures; Institution; Insulin; Insulin-Dependent Diabetes Mellitus; Investigational Therapies; Islet Cell; Islets of Langerhans; Islets of Langerhans Transplantation; Kidney Transplantation; Label; Pancreas; Phase; Procedures; Protocols documentation; Purpose; Research; Research Personnel; Resources; Safety; Screening procedure; Source; Testing; Therapeutic immunosuppression; Thinking; Transplant Recipients; United States National Institutes of Health; diabetic; follow-up; immunosuppressed; kidney allograft

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In Type 1 diabetes, islet cells in the pancreas, which make insulin, are thought to be destroyed in an immune response. Islet cell transplantation is a procedure that is being tested as an experimental therapy in individuals with difficult to control Type 1 diabetes who are already on immunosuppression following a kidney transplant. In this protocol, islet cells are harvested from a donor and cultured for infusion. This is an open label, feasibility study whose primary purpose is to test whether islet transplantation results seen in Edmonton, Canada can be repeated in immunosuppressed kidney transplant patients and to test the safety of this investigational procedure. The study will consist of a screening evaluation, the treatment phase, and a follow-up phase lasting approximately 12 months.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 在1型糖尿病中，胰腺中产生胰岛素的胰岛细胞被认为在免疫反应中被破坏。 胰岛细胞移植是一种正在测试的实验性治疗方法，用于难以控制的1型糖尿病患者，这些患者在肾移植后已经处于免疫抑制状态。 在该方案中，从供体收获胰岛细胞并培养用于输注。 这是一项开放标签、可行性研究，其主要目的是检测在加拿大埃德蒙顿观察到的胰岛移植结果是否可以在免疫抑制肾移植患者中重复，并检测该研究程序的安全性。 本研究将包括筛选评价、治疗期和持续约12个月的随访期。